Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an announcement.
Shanghai Bio-Heart Biological Technology Co., Ltd. has announced the termination of its 2022 H Share Incentive Scheme, along with the repurchase and cancellation of H shares, and a reduction in registered share capital. This decision, aimed at reducing administrative costs, will not impact the company’s public float or operational performance. The company plans to handle the repurchase and cancellation process in compliance with relevant regulations, pending shareholder approval at the upcoming annual general meeting.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a joint stock company based in China, operating in the biotechnology sector. The company focuses on developing and providing biological technology solutions, though specific products or services are not detailed in the announcement.
Average Trading Volume: 358,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue